IONS241220C50000
- 0.30
- 0.000.00%
Ionis Pharmaceuticals Newsroom
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $59 to $67
Sector Update: Health Care Stocks Mixed Premarket Friday
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
Express News | Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Ionis Pharmaceuticals Analyst Ratings
Ionis Pharmaceuticals Reports FDA Approval of Tryngolza
Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug
The rare disease drug Olezarsen under Ionis Pharmaceuticals (IONS.US) has been approved by the FDA.
The FDA has approved Olezarsen, a product of Ionis Pharmaceuticals, for the treatment of familial chylomicronemia syndrome (FCS).
Express News | Trading Halt: Halt Status Updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times
Express News | Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End
TRYNGOLZA (Olezarsen) Approved in U.S. as First-ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet
Ionis Pharmaceuticals Trading Halted, News Pending
Express News | Trading Halt: Halted at 4:28:30 P.m. ET - Trading Halt: Halt News Pending
Worst Performing Stocks for Tax Loss Selling – Wolfe
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
How Much Upside Is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $75
Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?
Ionis Pharmaceuticals Management to Meet With Oppenheimer